Loading clinical trials...
Loading clinical trials...
A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF CIM331 IN ATOPIC DERMATITIS PATIENTS WHO ARE INADEQUATELY CONTROLLED BY OR INTOLERANT TO TOPICAL THERAPY
Conditions
Interventions
nemolizumab (CIM331)
Placebo
Locations
18
United States
Anniston, Alabama, United States
San Diego, California, United States
Miami, Florida, United States
Alpharetta, Georgia, United States
Arlington Heights, Illinois, United States
Chicago, Illinois, United States
Start Date
November 1, 2013
Primary Completion Date
April 1, 2015
Completion Date
June 1, 2016
Last Updated
January 25, 2022
NCT06116526
NCT06461897
NCT07262983
NCT06389136
NCT06342713
NCT07223697
Lead Sponsor
Chugai Pharmaceutical
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions